Entecavir: profile and news

Novartis/Idenix: Entering Hepatitis B Market  Feb 9, 2006
...therapies already available, namely GlaxoSmithKline's Zeffix, Gilead's Hepsera (adefovir dipivoxil) and Bristol-Myers Squibb's Baraclude (entecavir), are able ... - International News Service,

Novartis/Idenix: entering hepatitis B market  Feb 7, 2006
...therapies already available, namely GlaxoSmithKline's Zeffix, Gilead's Hepsera (adefovir dipivoxil) and Bristol-Myers Squibb's Baraclude (entecavir), are able ... - Pharmaceutical Business Review

Tenofovir works as well for HBV in coinfected with 3TC resistance ...  Jan 27, 2006
Currently, two other oral anti-HBV drugs are approved in the United States - adefovir (Hepsera) and entecavir (Baraclude) - although only adefovir currently ... - Aidsmap,

BARACLUDE(TM) (entecavir) Two-year Data Analysis Did Not Detect ...  Nov 14, 2005
...naive chronic hepatitis B adult patients (with wild-type virus) treated with the Bristol-Myers Squibb Company oral antiviral agent BARACLUDE(TM) (entecavir). ... - Finanzen.net,

(PRN) - Nam Tai Electronics, Inc.: New Monthly Sales Record of $80 ...  Nov 14, 2005
...[+]. (PRN) - BARACLUDE(TM) (entecavir) Two-year Data Analysis Did Not Detect Emergence of Resistance in Nucleoside-Naive Chronic Hepatitis B Patients ... [+. ... - Bolsamania.com,

Entecavir joins the fight  Oct 22, 2005
At the symposium, Prof Lai was the main proponent of a new antiviral therapy, entecavir. Entecavir is the latest drug developed ... - Malaysia Star,

Help-atitis B!  Oct 22, 2005
The newest anti-viral agent on the block is entecavir, regarded as a much more potent agent that inhibits replication of the hepatitis B virus. ... - Malaysia Star,

Potent drug vs hepatitis B introduced  Sep 2, 2005
...disease. This latest treatment option is entecavir, which is considered the most potent oral antiviral drug for hepatitis to date. ... - INQ7 Interactive, Inc.,